Co-Diagnostics, Inc. (CODX) — DEF 14A Filings
All DEF 14A filings from Co-Diagnostics, Inc.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
CODX Seeks Reverse Split to Avoid Nasdaq Delisting
— Nov 10, 2025 Risk: high
Co-Diagnostics, Inc. (CODX) is seeking shareholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-30. This strategic move, unanimously -
Co-Diagnostics Executive Compensation Revealed
— Apr 14, 2025 Risk: medium
Co-Diagnostics, Inc. filed its DEF 14A on April 14, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes inf -
Co-Diagnostics Files Definitive Proxy Statement
— Jul 16, 2024 Risk: medium
Co-Diagnostics, Inc. filed its definitive proxy statement on July 16, 2024, for its annual meeting of shareholders. The filing outlines the company's governance
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX